Tuesday, November 19, 2019

Compounding Pharmacy and Its Owner Pay More Than $200,000 to Resolve False Claims Act Allegations Allegedly Violated an Anti-Kickback Law Relating to Tricare Prescriptions

A compounding pharmacy headquartered in Lenexa, Kansas, along with its owner, agreed to pay $205,000 to resolve allegations that the pharmacy submitted false claims to Tricare, the health care program for uniformed service members, retirees, and their families.  Neither the owner nor the pharmacy admitted liability as part of the settlement.   
Midwest Compounders, Inc., and its owner, Troy DeLong, agreed to settle allegations that claims submitted to Tricare from June 2012 to December 2014 were fraudulent for purposes of the False Claims Act.  The United States alleged that certain claims for compound medications during this period resulted from unlawful arrangements between the pharmacy and prescribers or marketers, or were otherwise improperly inflated in that the claims sought payment for medically unnecessary dosages or for redundant active ingredients. 
The allegations were made in a qui tam, or whistleblower, lawsuit.  The lawsuit was brought under the False Claims Act, which punishes violators who submit false claims to the government or who knowingly attempt to avoid an obligation to repay federal funds.  The whistleblower provisions allow private parties who have knowledge of fraud committed against the government to file suit on behalf of the government and share in any recovery.  The individual who filed this lawsuit received a share of the total amount recovered. 
The matter was handled by Assistant United States Attorney Jake Schunk and investigated by the Defense Criminal Investigative Service.  The lawsuit is captioned United States ex rel. Sten v. Midwest Compounders, et al.   

Press release found at      https://www.justice.gov/usao-ndia/pr/compounding-pharmacy-and-its-owner-pay-more-200000-resolve-false-claims-act-allegations


3 hours ago - FDA draft guidance allows for an animal drug to be compounded from bulk drug substances in limited circumstances for which there is no FDA-approved ...

AVMA: FDA issues draft guidance on compounding

FDA issues draft guidance on compounding: Today, the U.S. Food and Drug Administration’s Center for Veterinary Medicine (FDA CVM) issued new draft guidance for animal drug compounding. AVMA is analyzing this guidance to understand how it w…

updated November 19, 2019 FDA: Animal Drug Compounding

1 day ago - Drug compounding is the process of combining, mixing or altering ingredients to create a medication tailored to the needs of an individual animal or a small group of animals, and these drugs can play a critical role in veterinary medicine.
5 days ago - Compounding is generally a practice in which a licensed pharmacist, a licensed physician, or, in the case of an outsourcing facility, a person under the ...
4 days ago - compounding pharmacy headquartered in Lenexa, Kansas, along with its owner, agreed to pay $205,000 to resolve allegations that the pharmacy submitted ...